Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing

29 Aug 2022

Abstract excerpt

Recent advances in drug development have seen numerous successful clinical translations using synthetic antisense oligonucleotides (ASOs). However, major obstacles, such as challenging large-scale production, toxicity, localization of oligonucleotides in specific cellular compartments or tissues, and the high cost of treatment, need to be addressed. Thiomorpholino oligonucleotides (TMOs) are a recently developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Muscle Physiology and Disorders
Share to Neurogenetic and Muscular Disorders Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36037350
DOI: 10.1073/pnas.2207956119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicingPMID 36037350Read ↗

Next steps for the optimization of exon therapy for Duchenne muscular dystrophySemantic proximity Read ↗

Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseasesSemantic proximity Read ↗

Development of Therapeutic Splice-Switching OligonucleotidesSemantic proximity Read ↗

Modulation of RNA Splicing by Oligonucleotides: Mechanisms of Action and Therapeutic ImplicationsSemantic proximity Read ↗

Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular DystrophySemantic proximity Read ↗

Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.Semantic proximity Read ↗

The bench to bedside journey of tricyclo-DNA antisense oligonucleotides for the treatment of Duchenne muscular dystrophySemantic proximity Read ↗

Emerging Oligonucleotide Therapeutics for Rare Neuromuscular DiseasesSemantic proximity Read ↗

Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse modelSemantic proximity Read ↗

Splice-switching antisense oligonucleotides as therapeutic drugsSemantic proximity Read ↗

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseasesSemantic proximity Read ↗

Therapeutic antisense oligonucleotides for movement disordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.